
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists help manage type 2 diabetes by boosting insulin secretion when blood sugar is high and by lowering the amount of glucose produced by the liver. They are often introduced when first line oral medications such as metformin no longer keep blood sugar within the recommended range. In addition, several GLP-1 agonists have been linked to a lower risk of major cardiovascular events, such as heart attack and stroke, in patients with type 2 diabetes who already have heart disease.
In people who do not have diabetes, GLP-1 agonists including Wegovy and Saxenda are approved by the FDA as prescription treatments for weight loss. These medications work by increasing feelings of fullness and decreasing appetite, making it easier to reduce calorie intake without persistent hunger. Clinical trials have shown that when GLP-1 therapy is paired with lifestyle changes such as diet improvements and regular exercise, many patients achieve meaningful and sustained weight loss.
GLP-1 receptor agonists help regulate blood sugar by increasing insulin release after meals while at the same time lowering glucagon production from the liver. This combined effect prevents large, rapid spikes in blood glucose and supports steadier day to day glycemic control. Because their action is triggered mainly when glucose levels are elevated, the risk of hypoglycemia, or dangerously low blood sugar, is much lower than with many older diabetes medications.
One of the most important advantages of GLP-1 therapy is its ability to help people lose weight and keep it off over the long term. By slowing how quickly the stomach empties and sending signals to the brain that enhance feelings of fullness, GLP-1 medications make it easier to feel satisfied with smaller portions and less frequent snacking. Clinical research has shown that drugs such as liraglutide, semaglutide, and tirzepatide can produce meaningful and lasting weight loss when they are used together with healthy eating and regular physical activity.



GLP-1/GIP co-agonists stimulate both GLP-1 and GIP receptors, enhancing insulin release and controlling appetite more effectively than GLP-1 alone. These dual-action drugs provide a more robust method for managing blood sugar and hunger, making them a promising choice for treating obesity and type 2 diabetes.
GLP-1/glucagon co-agonists act on both GLP-1 and glucagon receptors to improve weight loss and boost energy metabolism while maintaining lean muscle mass, offering a balanced approach to metabolic health.

